DE69330784D1 - Grosse, latente komplexe von tgf-beta2 und tgf-beta3 - Google Patents

Grosse, latente komplexe von tgf-beta2 und tgf-beta3

Info

Publication number
DE69330784D1
DE69330784D1 DE69330784T DE69330784T DE69330784D1 DE 69330784 D1 DE69330784 D1 DE 69330784D1 DE 69330784 T DE69330784 T DE 69330784T DE 69330784 T DE69330784 T DE 69330784T DE 69330784 D1 DE69330784 D1 DE 69330784D1
Authority
DE
Germany
Prior art keywords
tgf
beta
beta3
beta2
ltbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330784T
Other languages
English (en)
Other versions
DE69330784T2 (de
Inventor
Kohei Miyazono
Carl-Henrik Heldin
Anders Olofsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research New York
Application granted granted Critical
Publication of DE69330784D1 publication Critical patent/DE69330784D1/de
Publication of DE69330784T2 publication Critical patent/DE69330784T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
DE69330784T 1992-01-27 1993-01-19 Grosse, latente komplexe von tgf-beta2 und tgf-beta3 Expired - Fee Related DE69330784T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/826,577 US5280109A (en) 1992-01-27 1992-01-27 Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2
PCT/US1993/000561 WO1993015114A1 (en) 1992-01-27 1993-01-19 Large, latent complexes of tgf-beta2 and tgf-beta3

Publications (2)

Publication Number Publication Date
DE69330784D1 true DE69330784D1 (de) 2001-10-25
DE69330784T2 DE69330784T2 (de) 2002-05-23

Family

ID=25246945

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330784T Expired - Fee Related DE69330784T2 (de) 1992-01-27 1993-01-19 Grosse, latente komplexe von tgf-beta2 und tgf-beta3

Country Status (9)

Country Link
US (2) US5280109A (de)
EP (1) EP0624165B1 (de)
JP (1) JP3390005B2 (de)
KR (1) KR100234497B1 (de)
AT (1) ATE205857T1 (de)
AU (1) AU660213B2 (de)
CA (1) CA2128784C (de)
DE (1) DE69330784T2 (de)
WO (1) WO1993015114A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229495A (en) * 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5656450A (en) * 1994-05-27 1997-08-12 Board Of Regents, The University Of Texas System Activation of latent transforming growth factor β by matrix vesicles
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
WO1991019513A1 (en) * 1990-06-20 1991-12-26 Bristol-Myers Squibb Company METHODS OF MODULATING BLOOD PRESSURE USING TGF-β AND ANTAGONISTS THEREOF

Also Published As

Publication number Publication date
CA2128784A1 (en) 1993-08-05
AU3481793A (en) 1993-09-01
WO1993015114A1 (en) 1993-08-05
EP0624165B1 (de) 2001-09-19
US5346993A (en) 1994-09-13
EP0624165A4 (en) 1996-01-24
EP0624165A1 (de) 1994-11-17
AU660213B2 (en) 1995-06-15
JPH07503251A (ja) 1995-04-06
DE69330784T2 (de) 2002-05-23
CA2128784C (en) 2002-04-30
US5280109A (en) 1994-01-18
KR100234497B1 (ko) 1999-12-15
JP3390005B2 (ja) 2003-03-24
ATE205857T1 (de) 2001-10-15

Similar Documents

Publication Publication Date Title
DE69330784T2 (de) Grosse, latente komplexe von tgf-beta2 und tgf-beta3
DK0724456T3 (da) CD40-Antistoffer
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
DE69312218D1 (de) Redistribution von organischen Polycarbonatzusammensetzungen
AP9200410A0 (en) Retroviral protease inhibitors.
DE69634438D1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
ATE110742T1 (de) Peptid-verbindungen.
DE69416518D1 (de) Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
NO904292L (no) Fremgangsmaate for fremstilling av antikoagulerende peptider.
NO894880D0 (no) Fremgangsmaate for fremstilling av antikoagulerende peptider.
ES2094228T3 (es) Peptidos anticoagulantes.
DE69433745D1 (de) Modifizierte, verkürzte regulatoren des komplementsystems
NO962204L (no) Dobbeltkjedede hemoregulatoriske peptider

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee